New and experimental HIV treatments: latest news

New and experimental HIV treatments features

New and experimental HIV treatments in your own words

New and experimental HIV treatments news from aidsmap

More news

New and experimental HIV treatments news selected from other sources

  • Gilead's first big TV push for triple combo Biktarvy showcases HIV diversity

    Gilead Sciences wanted to represent the wide range of people living with HIV in its first national TV campaign for Biktarvy. So they chose black, Latino, male, female, gay, bisexual and transgender actors for an ad that encourages people with HIV to “keep being you.”

    18 April 2019 | FiercePharma
  • Novel Antibody May Suppress HIV for Up to Four Months

    Regular infusions of an antibody that blocks the HIV binding site on human immune cells may have suppressed levels of HIV for up to four months in people undergoing a short-term pause in their antiretroviral therapy (ART) regimens, according to a report published online today in The New England Journal of Medicine.

    18 April 2019 | NIAID
  • Dovato Is a Newly Approved Two-Drug HIV Regimen. Do Fewer Drugs Mean a Lower-Cost HIV Treatment?

    When HIV drugmaker ViiV announced in late 2017 that it had received Food and Drug Administration (FDA) approval for Juluca (dolutegravir/rilpivirine), the first effective two-drug, single-pill HIV regimen in the modern treatment era, community activists hoped that its price would reflect the fact that it contained one drug fewer than three-drug tablets like Complera (rilpivirine/tenofovir disoproxil fumarate/FTC), Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide), Stribild (cobicistat/elvitegravir/FTC/tenofovir disoproxil fumarate), and Triumeq (abacavir/dolutegravir/lamivudine), all of which are generally priced between $2,600 and $3,500 a month in the U.S.

    15 April 2019 | The Body
  • FDA approves first two-drug complete regimen for HIV-infected patients who have never received antiretroviral treatment

    The U.S. Food and Drug Administration today approved Dovato (dolutegravir and lamivudine), as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults with no antiretroviral treatment history and with no known or suspected substitutions associated with resistance to the individual components of Dovato. This is the first FDA-approved two-drug, fixed-dose, complete regimen for HIV-infected adults who have never received treatment for HIV.

    09 April 2019 | Food & Drug Administration
  • HIV Drugs With Fewer Side Effects Need More FDA Support

    New medicines providing a better quality of life should always be top priority when asking for federal support.

    27 March 2019 | HivPlusMag.com
  • Why 1 Top Analyst Thinks Gilead Sciences Will Soar More Than 25%

    RBC Capital Markets analyst Brian Abrahams specifically mentioned a somewhat surprising reason to be excited about Gilead's prospects. He thinks that experimental HIV drug GS-6207 could be a transformative catalyst for Gilead. But GS-6207 is only in phase 1 clinical testing. It could take years for the drug to reach the market.

    24 March 2019 | Motley Fool
  • Trogarzo’s Effects on Hard-to-Treat HIV Are Stable Over Two Years

    Researchers followed a small group of people with highly drug-resistant virus taking Trogarzo (ibalizumab-uiyk) plus an optimized background regimen.

    20 March 2019 | Poz
  • HIV Drug Aiming to Free Patients From Daily Doses Nears Market

    A once-a-month shot promising to free patients from daily doses of treatment for HIV, the virus that causes AIDS, is expected to reach the market early next year after hitting goals in a pair of studies.

    08 March 2019 | Bloomberg
  • Using anti-cancer immunotherapy to fight HIV

    Researchers at the University of Montreal Hospital Research Centre (CRCHUM) have shown that immunotherapy treatments against cancer could reduce the amount of virus that persists in people on triple therapy. In a study published in the journal Nature Communications, they show, in the cells of people living with HIV, how these therapies reveal the virus - until now hidden in the hollows of infected cells - to the immune system.

    20 February 2019 | Eurekalert Medicine & Health
  • CytoDyn wins key concession from FDA for flagship HIV drug leronlimab trial

    The FDA is allowing CytoDyn to increase the dose of the HIV drug leronlimab which patients in its clinical trial are receiving.

    04 February 2019 | Proactive Investors USA & Canada
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.